Literature DB >> 23670723

Assessment of case definitions for identifying acute liver injury in large observational databases.

Aaron J Katz1, Patrick B Ryan, Judith A Racoosin, Paul E Stang.   

Abstract

BACKGROUND: Determining the aetiology of acute liver injury (ALI) may be challenging to both clinicians and researchers. Observational research is particularly useful in studying rare medical outcomes such as ALI; however, case definitions for ALI in previous observational studies lack consistency and sensitivity. ALI is a clinically important condition with various aetiologies, including drug exposure.
OBJECTIVE: The aim of this study was to evaluate four distinct case definitions for ALI across a diverse set of large observational databases, providing a better understanding of ALI prevalence and natural history. DATA SOURCES: Seven healthcare databases: GE Healthcare, MarketScan(®) Lab Database, Humana Inc., Partners HealthCare System, Regenstrief Institute, SDI Health (now IMS Health, Inc.), and the National Patient Care Database of the Veterans Health Administration.
METHODS: We evaluated prevalence of ALI through the application of four distinct case definitions across seven observational healthcare databases. We described how laboratory and clinical characteristics of identified case populations varied across definitions and examined the prevalence of other hepatobiliary disorders among identified ALI cases that may decrease suspicion of drug-induced liver injury (DILI) in particular.
RESULTS: This study demonstrated that increasing the restrictiveness of the case definition resulted in fewer cases, but greater prevalence of ALI clinical features. Considerable heterogeneity in the frequency of laboratory testing and results observed among cases meeting the most restrictive definition suggests that the clinical features, monitoring patterns and suspicion of ALI are highly variable among patients.
CONCLUSIONS: Creation of four distinct case definitions and application across a disparate set of observational databases resulted in significant variation in the prevalence of ALI. A greater understanding of the natural history of ALI through examination of electronic healthcare data can facilitate development of reliable and valid ALI case definitions that may enhance the ability to accurately identify associations between ALI and drug exposures. Considerable heterogeneity in laboratory values and frequency of laboratory testing among individuals meeting the criteria for ALI suggests that the evaluation of ALI is highly variable.

Entities:  

Mesh:

Year:  2013        PMID: 23670723     DOI: 10.1007/s40264-013-0060-8

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  27 in total

1.  Pharmacoepidemiology safety study of fibrate and statin concomitant therapy.

Authors:  Cheryl Enger; Robert Gately; Eileen E Ming; Steve J Niemcryk; Laura Williams; Andrew T McAfee
Journal:  Am J Cardiol       Date:  2010-10-14       Impact factor: 2.778

2.  Searching for a needle in a haystack: use of ICD-9-CM codes in drug-induced liver injury.

Authors:  Kartik Jinjuvadia; Wendy Kwan; Robert J Fontana
Journal:  Am J Gastroenterol       Date:  2007-07-27       Impact factor: 10.864

3.  Results from a rosuvastatin historical cohort study in more than 45,000 Dutch statin users, a PHARMO study.

Authors:  W G Goettsch; E M Heintjes; J J P Kastelein; T J Rabelink; Saga Johansson; R M C Herings
Journal:  Pharmacoepidemiol Drug Saf       Date:  2006-07       Impact factor: 2.890

4.  Association between tetracycline or doxycycline and hepatotoxicity: a population based case-control study.

Authors:  P C Heaton; S R Fenwick; D E Brewer
Journal:  J Clin Pharm Ther       Date:  2007-10       Impact factor: 2.512

5.  No risk of drug-associated liver injury with alpha1-adrenoreceptor blocking agents in men with BPH: results from an observational study using the GPRD.

Authors:  Gary M Clifford; John Logie; Richard D T Farmer
Journal:  Pharmacoepidemiol Drug Saf       Date:  2005-02       Impact factor: 2.890

6.  Acute liver disease associated with erythromycins, sulfonamides, and tetracyclines.

Authors:  J L Carson; B L Strom; A Duff; A Gupta; M Shaw; F E Lundin; K Das
Journal:  Ann Intern Med       Date:  1993-10-01       Impact factor: 25.391

7.  Acute and clinically relevant drug-induced liver injury: a population based case-control study.

Authors:  Francisco J de Abajo; Dolores Montero; Mariano Madurga; Luis A García Rodríguez
Journal:  Br J Clin Pharmacol       Date:  2004-07       Impact factor: 4.335

8.  Adverse events associated with prolonged antibiotic use.

Authors:  Sharon B Meropol; K Arnold Chan; Zhen Chen; Jonathan A Finkelstein; Sean Hennessy; Ebbing Lautenbach; Richard Platt; Stephanie D Schech; Deborah Shatin; Joshua P Metlay
Journal:  Pharmacoepidemiol Drug Saf       Date:  2008-05       Impact factor: 2.890

9.  The increased risk of hospitalizations for acute liver injury in a population with exposure to multiple drugs.

Authors:  S Pérez Gutthann; L A García Rodríguez
Journal:  Epidemiology       Date:  1993-11       Impact factor: 4.822

Review 10.  Review article: the diagnosis and management of alcoholic hepatitis.

Authors:  S M Cohen; J Ahn
Journal:  Aliment Pharmacol Ther       Date:  2009-03-26       Impact factor: 8.171

View more
  7 in total

1.  Risk of severe acute liver injury among patients with brain cancer treated with temozolomide: a nested case-control study using the healthcore integrated research database.

Authors:  Vibha C A Desai; Scott C Quinlan; Anne C Deitz; Jinghua He; Crystal N Holick; Stephan Lanes
Journal:  J Neurooncol       Date:  2017-07-17       Impact factor: 4.130

2.  Alternative outcome definitions and their effect on the performance of methods for observational outcome studies.

Authors:  Christian G Reich; Patrick B Ryan; Martijn J Schuemie
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

3.  How well do various health outcome definitions identify appropriate cases in observational studies?

Authors:  Richard A Hansen; Michael D Gray; Brent I Fox; Joshua C Hollingsworth; Juan Gao; Peng Zeng
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

4.  Ascertainment of acute liver injury in two European primary care databases.

Authors:  A Ruigómez; R Brauer; L A García Rodríguez; C Huerta; G Requena; M Gil; Francisco de Abajo; G Downey; A Bate; M Feudjo Tepie; M de Groot; R Schlienger; R Reynolds; O Klungel
Journal:  Eur J Clin Pharmacol       Date:  2014-07-29       Impact factor: 2.953

Review 5.  Defining a reference set to support methodological research in drug safety.

Authors:  Patrick B Ryan; Martijn J Schuemie; Emily Welebob; Jon Duke; Sarah Valentine; Abraham G Hartzema
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

6.  Risk of Acute Liver Injury in Agomelatine and Other Antidepressant Users in Four European Countries: A Cohort and Nested Case-Control Study Using Automated Health Data Sources.

Authors:  Manel Pladevall-Vila; Anton Pottegård; Tania Schink; Johan Reutfors; Rosa Morros; Beatriz Poblador-Plou; Antje Timmer; Joan Forns; Maja Hellfritzsch; Tammo Reinders; David Hägg; Maria Giner-Soriano; Alexandra Prados-Torres; Miguel Cainzos-Achirica; Jesper Hallas; Lena Brandt; Jordi Cortés; Jaume Aguado; Gabriel Perlemuter; Bruno Falissard; Jordi Castellsagué; Emmanuelle Jacquot; Nicolas Deltour; Susana Perez-Gutthann
Journal:  CNS Drugs       Date:  2019-04       Impact factor: 5.749

7.  Seasonality in acute liver injury? Findings in two health care claims databases.

Authors:  Rachel B Weinstein; Martijn J Schuemie; Patrick B Ryan; Paul E Stang
Journal:  Drug Healthc Patient Saf       Date:  2016-03-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.